F Deisenhammer

Summary

Affiliation: Innsbruck Medical University
Country: Austria

Publications

  1. pmc Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosis
    Rainer Ehling
    Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    Fluids Barriers CNS 8:25. 2011
  2. pmc IgG-index predicts neurological morbidity in patients with infectious central nervous system diseases
    Peter Lackner
    Department of Neurology, Innsbruck Medical University, Austria
    BMC Infect Dis 10:202. 2010
  3. ncbi request reprint EFNS guidelines on disease-specific CSF investigations
    F Deisenhammer
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Eur J Neurol 16:760-70. 2009
  4. doi request reprint Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes
    Florian Deisenhammer
    Department of Neurology, Innsbruck Medical University, Anichstrasse 35, Innsbruck 6020, Austria
    CNS Drugs 23:379-96. 2009
  5. doi request reprint High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study
    A Millonig
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Mult Scler 15:977-83. 2009
  6. ncbi request reprint Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies
    C Gneiss
    Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    J Neuroimmunol 174:174-9. 2006
  7. ncbi request reprint Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients
    C Gneiss
    Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria
    Mult Scler 12:731-7. 2006
  8. ncbi request reprint A comparative study of the relative bioavailability of different interferon beta preparations
    F Deisenhammer
    Department of Neurology, University of Innsbruck, Austria
    Neurology 54:2055-60. 2000
  9. doi request reprint Comparative study of four different assays for the detection of binding antibodies against interferon-beta
    C Gneiss
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Mult Scler 14:830-6. 2008
  10. ncbi request reprint Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity
    C Gneiss
    Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
    Mult Scler 10:507-10. 2004

Collaborators

Detail Information

Publications26

  1. pmc Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosis
    Rainer Ehling
    Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    Fluids Barriers CNS 8:25. 2011
    ..abstract:..
  2. pmc IgG-index predicts neurological morbidity in patients with infectious central nervous system diseases
    Peter Lackner
    Department of Neurology, Innsbruck Medical University, Austria
    BMC Infect Dis 10:202. 2010
    ..In this retrospective cross-sectional study the prognostic value of basic cerebrospinal fluid (CSF) parameters in patients with bacterial meningitis, viral meningoencephalitis and leptomeningeal metastases were evaluated...
  3. ncbi request reprint EFNS guidelines on disease-specific CSF investigations
    F Deisenhammer
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Eur J Neurol 16:760-70. 2009
    ..Elevated CSF neurofilament (Nf) levels probably reflect acute neuronal degeneration. The prognostic value of CSF Nf levels is highest in acute conditions such as subarachnoid hemorrhage, acute optic neuritis and neuromyelitis optica...
  4. doi request reprint Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes
    Florian Deisenhammer
    Department of Neurology, Innsbruck Medical University, Anichstrasse 35, Innsbruck 6020, Austria
    CNS Drugs 23:379-96. 2009
    ..NAbs against natalizumab occur less frequently (6%) and, like NAbs against IFNbeta, they are associated with a loss of clinical and radiological efficacy of the drug...
  5. doi request reprint High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study
    A Millonig
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Mult Scler 15:977-83. 2009
    ..To date, there are no anti-NAB strategies available. The primary objective of this trial was to investigate whether intravenous IFNbeta-1b can restore bioactivity in NAB-positive patients with MS...
  6. ncbi request reprint Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies
    C Gneiss
    Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    J Neuroimmunol 174:174-9. 2006
    ..A significant positive correlation between relative affinity values and therapy duration indicates affinity maturation as another qualitative factor in IFNbeta neutralization...
  7. ncbi request reprint Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients
    C Gneiss
    Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria
    Mult Scler 12:731-7. 2006
    ....
  8. ncbi request reprint A comparative study of the relative bioavailability of different interferon beta preparations
    F Deisenhammer
    Department of Neurology, University of Innsbruck, Austria
    Neurology 54:2055-60. 2000
    ..These products differ with respect to the recommended dose, the dosage regimen, and the injection route. This study compared the relative biologic activity of these three products in vitro and in vivo...
  9. doi request reprint Comparative study of four different assays for the detection of binding antibodies against interferon-beta
    C Gneiss
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Mult Scler 14:830-6. 2008
    ..Binding antibodies (BAB) against interferon-beta (IFNbeta) are often determined as screening assays before performing an expensive and elaborate neutralizing antibody (NAB) test...
  10. ncbi request reprint Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity
    C Gneiss
    Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
    Mult Scler 10:507-10. 2004
    ..It has been reported that in some patients with MS who develop neutralizing antibodies (NAbs) against interferon beta (IFNbeta), antibody levels can initially increase and then decrease thereafter even when treatment is continued...
  11. ncbi request reprint Smoking is a risk factor for early conversion to clinically definite multiple sclerosis
    F Di Pauli
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Mult Scler 14:1026-30. 2008
    ..In this study, we determined whether smoking is a risk factor for early conversion to clinically definite multiple sclerosis after a clinically isolated syndrome...
  12. ncbi request reprint Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b
    F Deisenhammer
    Department of Neurology, University of Innsbruck, Austria
    J Interferon Cytokine Res 21:167-71. 2001
    ..3200, p = 0.01; 1600 vs. 400, p = 0.0004; 200 vs. 0, p = 0.004). It is concluded that the development of NAB is related to both the quantity and the quality of the antibodies against IFN-beta1b...
  13. doi request reprint Olfactory threshold is impaired in early, active multiple sclerosis
    A Lutterotti
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Mult Scler 17:964-9. 2011
    ..Olfactory dysfunction has been reported in multiple sclerosis (MS). However, to date no data are available on different qualities of olfactory function, namely odour identification, odour discrimination and odour perception threshold...
  14. doi request reprint MxA protein--an interferon beta biomarker in primary progressive multiple sclerosis patients
    A Millonig
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Eur J Neurol 15:822-6. 2008
    ..Myxovirus resistance protein A (MxA)--a marker of IFNbeta bioactivity--was correlated with the clinical response during an uncontrolled trial, investigating the safety of IFNbeta-1b in primary progressive (PPMS) patients...
  15. ncbi request reprint Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis
    R Ehling
    Clinical Department of Neurology, Medical University of Innsbruck, A 6020 Innsbruck, Austria
    Mult Scler 10:601-6. 2004
    ..Our findings support the use of serum antibodies to NF-L as a marker for axonal destruction...
  16. doi request reprint Decision-making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS)
    F Fazekas
    Department of Neurology, Medical University of Graz, Graz, Austria
    Eur J Neurol 17:852-60. 2010
    ..How this occurs in a routine setting is barely known. The aim of the study was to investigate the decision-making process regarding immediate or later DMT and the ensuing impact on CIS patients in Austria...
  17. ncbi request reprint Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis
    R Egg
    Department of Neurology, University of Innsbruck, Austria
    Mult Scler 7:285-9. 2001
    ..However, patients treated either with intravenous immunoglobulins or interferon-beta showed a significant reduction of anti-MOG IgG3 antibodies...
  18. ncbi request reprint Increased intrathecal production of apolipoprotein D in multiple sclerosis
    M Reindl
    Department of Neurology, University of Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria
    J Neuroimmunol 119:327-32. 2001
    ..CSF apoD levels and apoD indices correlate with MS disease duration but not with disability or age. Finally, we found that corticosteroid treatment resulted in significantly elevated CSF apoD levels...
  19. ncbi request reprint Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis
    G Stockhammer
    Departments of Neurology, University of Innsbruck, Innsbruck, Austria
    Neurology 54:1670-6. 2000
    ..To determine the value of vascular endothelial growth factor (VEGF) in CSF as a marker for carcinomatous meningitis (CM)...
  20. ncbi request reprint Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force
    F Deisenhammer
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Eur J Neurol 13:913-22. 2006
    ..Computed tomography-negative intrathecal bleeding should be investigated by bilirubin detection...
  21. ncbi request reprint A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta
    M Kob
    Department of Neurology, University of Innsbruck, Innsbruck, Austria
    Mult Scler 9:32-5. 2003
    ..However, this is outweighed by the procedural advantage of the assay, which is simpler, quicker and much less expensive...
  22. ncbi request reprint Mutations in the gene for toll-like receptor 4 and multiple sclerosis
    M Reindl
    Department of Neurology, University of Innsbruck, Innsbruck, Austria
    Tissue Antigens 61:85-8. 2003
    ..Our data indicate that these TLR4 polymorphisms have no influence on the incidence, progression and inflammatory parameters of MS...
  23. ncbi request reprint Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury
    G Franz
    Department of Neurology, University of Innsbruck, Austria
    Neurology 60:1457-61. 2003
    ..To determine whether CSF amyloid beta 1-42 (Abeta-42) and tau have predictive value for prognosis after head injury...
  24. ncbi request reprint Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development
    H Hegen
    Department of Neurology, Innsbruck Medical University, Austria
    Mult Scler 20:577-87. 2014
    ..Neutralizing antibodies (NAb) affect efficacy of interferon-beta (IFN-b) treatment in multiple sclerosis (MS) patients. NAbs evolve in up to 44% of treated patients, usually between 6-18 months on therapy...
  25. ncbi request reprint Correlation between the IgG index, oligoclonal bands in CSF, and the diagnosis of demyelinating diseases
    I Mayringer
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Eur J Neurol 12:527-30. 2005
    ..We conclude that quantitative assessment of CSF-IgG can be useful because it is easier and quicker to perform than IEF but cannot replace IEF in general because this is the most sensitive method to detect abnormal IgG in CSF...
  26. ncbi request reprint Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group
    F Fazekas
    Department of Neurology, Karl-Franzens University, Graz, Austria
    Lancet 349:589-93. 1997
    ..INTERPRETATION: Monthly IVIg is an effective and well-tolerated treatment for patients with relapsing-remitting multiple sclerosis...